Oxford Cancer Biomarkers

Biotechnology Research • Oxford, England, United Kingdom • 1-10 Employees

Company overview

Headquarters	The Magdalen Centre, Oxford, Oxfordshire OX4 4GA, GB
Phone number	+441864784743
Websites	oxfordcancerbiomarkers.com oxfordbio.com
NAICS	541714
SIC	873
Keywords	Cancer Biomarkers, Digital Health, Genotyping, Personalised Medicine, Diagnostic Tests, Digital Pathology
Founded	2012
Employees	1-10
Socials

Key Contact at Oxford Cancer Biomarkers

Susan Fotheringham

Science Director - Consultant

Oxford Cancer Biomarkers Email Formats

Oxford Cancer Biomarkers uses 1 email format. The most common is {first name} (e.g., john@oxfordcancerbiomarkers.com), used 100% of the time.

Format	Example	Percentage
{first name}	john@oxfordcancerbiomarkers.com	100%

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford. Oxford Cancer Biomarkers range of predictive biomarkers will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 20 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. OncoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer.

Oxford Cancer Biomarkers revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,000,000
Total funding	$1,800,000

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Head

Employees by Department

Oxford Cancer Biomarkers has 2 employees across 2 departments.

Departments

Number of employees

Funding Data

Explore Oxford Cancer Biomarkers's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-04-03	9	$1,800,000

Funding Insights

$1,800,000

Total funding amount

$1,800,000

Most recent funding amount

Number of funding rounds

Oxford Cancer Biomarkers Tech Stack

Discover the technologies and tools that power Oxford Cancer Biomarkers's digital infrastructure, from frameworks to analytics platforms.

Gravity Forms

Form builders

WP Rocket

Caching

Google Maps

Maps

Animate.css

UI frameworks

Beaver Builder

WordPress plugins

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Blocksy

WordPress themes

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

PHP

Programming languages

WordPress

Blogs

Frequently asked questions

Oxford Cancer Biomarkers is located in Oxford, England, GB.

You can reach Oxford Cancer Biomarkers at +441864784743.

Oxford Cancer Biomarkers was founded in 2012, making it 14 years old. The company has established itself as a significant player in its industry over this time.

Oxford Cancer Biomarkers has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Oxford Cancer Biomarkers has raised a total of $1,800,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Oxford Cancer Biomarkers

Susan Fotheringham

Science Director - Consultant

4.8

40,000 users